Assembly Biosciences (NASDAQ: ASMB) officer logs RSU grant, tax sell-to-cover

Rhea-AI Filing Summary

Assembly Biosciences PFO and PAO Jeanette M. Bjorkquist reported a mix of equity grants and related share sales. She received a grant of 6,500 restricted stock units (RSUs), scheduled to vest in four equal installments on March 29 of 2027, 2028, 2029, and 2030, assuming continuous service. Footnotes state that RSUs represent 65% of her annual equity grant and that the remaining 35% of RSUs is contingent on stockholder approval of an amendment to the company’s 2018 Stock Incentive Plan to increase authorized shares. On March 30, 2026, she sold a total of 328 common shares in open-market transactions at weighted average prices of $26.6502 and $27.49 per share to cover tax withholding obligations under a mandatory sell-to-cover rule, described as a non-discretionary transaction. Following these transactions, she directly holds 11,089 common shares.

Insider Trade Summary

Net Seller: 328 shares ($8,755)

Net Sell 3 txns

Insider Bjorkquist Jeanette M

Role PFO and PAO

Sold 328 shs ($9K)

Type	Security	Shares	Price	Value
Sale	Common Stock	312	$26.6502	$8K
Sale	Common Stock	16	$27.49	$439.84
Grant/Award	Common Stock	6,500	$0.00	--

Holdings After Transaction: Common Stock — 11,105 shares (Direct)

Footnotes (1)

1. Grant of restricted stock units ("RSUs"). The RSUs vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2027; March 29, 2028; March 29, 2029; and March 29, 2030. RSUs represent 65% of the reporting person's annual equity grant. The remaining 35% of the RSUs granted are contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan") that increases the number of shares of common stock authorized for issuance under the Plan. Reflects 300 fewer shares than were included in Column 5 on reporting person's prior Form 4 due to an administrative error. The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.35 to $27.26, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.39 to $27.84, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

Key Figures

RSU grant: 6,500 RSUs RSU vesting schedule: 4 equal installments Shares sold for taxes: 328 shares +5 more

8 metrics

RSU grant 6,500 RSUs Granted March 29, 2026 as part of annual equity grant

RSU vesting schedule 4 equal installments Vesting on March 29 of 2027, 2028, 2029, 2030

Shares sold for taxes 328 shares Open-market sales on March 30, 2026 to cover tax withholding

Sale price tranche 1 $26.6502 per share Weighted average price for 312 sold shares

Sale price tranche 2 $27.49 per share Price for 16 sold shares

Post-transaction holdings 11,089 shares Common stock held directly after reported transactions

Annual grant RSU portion 65% RSUs as percentage of annual equity grant

Contingent RSU portion 35% RSUs contingent on stockholder approval of Plan amendment

Key Terms

restricted stock units ("RSUs"), sell-to-cover, tax withholding obligations, weighted average price, +1 more

5 terms

restricted stock units ("RSUs") financial

"Grant of restricted stock units ("RSUs"). The RSUs vest in four equal installments"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

sell-to-cover financial

"requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

tax withholding obligations financial

"shares sold by the reporting person to cover tax withholding obligations in connection with the vesting"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Amended and Restated 2018 Stock Incentive Plan financial

"amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bjorkquist Jeanette M

(Last) (First) (Middle)

C/O ASSEMBLY BIOSCIENCES, INC.

TWO TOWER PLACE, 7TH FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ASSEMBLY BIOSCIENCES, INC. [ ASMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PFO and PAO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/29/2026		A		6,500(1)(2)	A	$0	11,417(3)	D
Common Stock	03/30/2026		S(4)		312	D	$26.6502(5)	11,105	D
Common Stock	03/30/2026		S(4)		16	D	$27.49(6)	11,089	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock units ("RSUs"). The RSUs vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2027; March 29, 2028; March 29, 2029; and March 29, 2030.

2. RSUs represent 65% of the reporting person's annual equity grant. The remaining 35% of the RSUs granted are contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan") that increases the number of shares of common stock authorized for issuance under the Plan.

3. Reflects 300 fewer shares than were included in Column 5 on reporting person's prior Form 4 due to an administrative error.

4. The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sale is mandated by an administrative rule adopted by the Compensation Committee of the Issuer's Board of Directors that requires the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary transaction by the reporting person.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.35 to $27.26, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.39 to $27.84, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

	/s/ John O. Gunderson, as Attorney-in-Fact	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ASMB officer Jeanette Bjorkquist report in her latest Form 4?

She reported a grant of 6,500 restricted stock units and the sale of 328 common shares. The sales were to cover tax withholding obligations tied to RSU vesting under a mandatory sell-to-cover rule.

How many Assembly Biosciences (ASMB) RSUs were granted to Jeanette Bjorkquist?

She was granted 6,500 restricted stock units. These RSUs vest in four equal installments on March 29 of 2027, 2028, 2029, and 2030, provided she remains in continuous service with the company.

Why did ASMB’s PFO and PAO sell 328 common shares?

The 328 common shares were sold to cover tax withholding obligations arising from RSU vesting and settlement. A Compensation Committee rule mandates using a sell-to-cover transaction, so the sales are described as non-discretionary for the reporting person.

What prices were received in the ASMB insider’s tax-related share sales?

She sold 312 shares at a weighted average price of $26.6502 and 16 shares at $27.49. Footnotes note that each weighted average reflects multiple trades within specified intraday price ranges for the company’s common stock.

How many ASMB shares does Jeanette Bjorkquist hold after these transactions?

After the reported RSU activity and tax-related sales, she directly holds 11,089 shares of Assembly Biosciences common stock. A footnote also corrects a prior Form 4 holding figure by reducing it by 300 shares due to an administrative error.

Are all of the ASMB RSUs granted to Bjorkquist currently effective?

No. Footnotes explain that RSUs represent 65% of her annual equity grant. The remaining 35% of RSUs is contingent on stockholder approval of an amendment increasing shares authorized under the company’s 2018 Stock Incentive Plan.